ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Delayed Salvage Radiation Therapy Guided by Contrast-Enhanced Local and Whole-Body Diffusion-Weighted Magnetic Resonance Imaging During Prostate-Specific-Antigen-Based Surveillance After Radical Prostatectomy: A Retrospective Cohort Study.Advances in radiation oncology · 2026Article
- Editorial Comment on [International journal of urology : official journal of the Japanese Urological Association · 2026Article
- [International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.Future oncology (London, England) · 2026Article
- Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy.Advances in radiation oncology · 2026Article
- Article
- Article
- Optimizing salvage radiotherapy in prostate cancer: the emerging role of prostate-specific membrane antigen positron emission tomography/computed tomography.Translational andrology and urology · 2025Article
- Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.European journal of nuclear medicine and molecular imaging · 2024Article
- Application of next-generation imaging in biochemically recurrent prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- A bicentric retrospective study of the correlation of EAU BCR risk groups withScientific reports · 2024Article
- Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [Cancers · 2024Article
- Impact of PSMA PET on Prostate Cancer Management.Current treatment options in oncology · 2024Review
- Initial Experience withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Article
- Article
- Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.Biomedicines · 2023Article
- Article
- Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [Scientific reports · 2023Article
- Evaluation of [EJNMMI research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 3 countries.
Funding
Abstract
The European Association of Urology (EAU) prostate cancer guidelines panel recommends risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk of progression or metastatic disease. The rapidly growing availability of PSMA-directed PET imaging will impact prostate cancer staging. We determined the rates of local and metastatic disease in BCR and biochemical persistence (BCP) of prostate cancer stratified by EAU BCR risk groups and BCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.